Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events
6 Months Ended
Jan. 31, 2017
Subsequent Events [Abstract]  
Subsequent Events

Note 11—Subsequent Events


On February 27, 2017, the Company announced that it received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for its lead product candidate ImmunoPulse® IL-12. This could qualify ImmunoPulse® IL-12 for expedited FDA review, a rolling Biologics License Application review, and other benefits.